KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Payables (2016 - 2026)

Evolent Health has reported Payables over the past 11 years, most recently at $59.8 million for Q4 2025.

  • For Q4 2025, Payables fell 77.65% year-over-year to $59.8 million; the TTM value through Dec 2025 reached $59.8 million, down 77.65%, while the annual FY2025 figure was $59.8 million, 77.65% down from the prior year.
  • Payables for Q4 2025 was $59.8 million at Evolent Health, down from $77.3 million in the prior quarter.
  • Over five years, Payables peaked at $267.5 million in Q4 2024 and troughed at $37.8 million in Q3 2021.
  • A 5-year average of $90.2 million and a median of $62.9 million in 2022 define the central range for Payables.
  • On a YoY basis, Payables climbed as much as 518.96% in 2025 and fell as far as 77.65% in 2025.
  • Year by year, Payables stood at $96.1 million in 2021, then tumbled by 40.5% to $57.2 million in 2022, then dropped by 15.62% to $48.2 million in 2023, then soared by 454.43% to $267.5 million in 2024, then crashed by 77.65% to $59.8 million in 2025.
  • Business Quant data shows Payables for EVH at $59.8 million in Q4 2025, $77.3 million in Q3 2025, and $241.6 million in Q2 2025.